
Author Index Volume 1

The volume numbers are printed in italics

Angibaud P, see End DW (2007) *I*: 115–150

Arts J, see ten Holte P (2007) *I*: 273–311

Blake JF, see Wallace EM (2007) *I*: 65–114

de Bono JS, see ten Holte P (2007) *I*: 273–311

Boschelli DH (2007) Bcr-Abl Kinase Inhibitors. *I*: 387–424

Bradbury RH (2007) Overview. *I*: 1–17

Van Emelen K, see ten Holte P (2007) *I*: 273–311

End DW, Mevellec L, Angibaud P (2007) Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic. *I*: 115–150

Fong PC, see ten Holte P (2007) *I*: 273–311

Galemmo Jr RA, see Moriarty KJ (2007) *I*: 189–271

Garcia-Echeverria C (2007) Survival Signaling. *I*: 151–188

Hoffmann J, Sommer A (2007) Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer. *I*: 1–64

ten Holte P, Van Emelen K, Janicot M, Fong PC, de Bono JS, Arts J (2007) HDAC Inhibition in Cancer Therapy: an Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. *I*: 273–311

Janicot M, see ten Holte P (2007) *I*: 273–311

Johnson DL, see Moriarty KJ (2007) *I*: 189–271

Koblish H, see Moriarty KJ (2007) *I*: 189–271

Laird ER, see Wallace EM (2007) *I*: 65–114

Lyssikatos J, see Wallace EM (2007) *I*: 65–114

Mevellec L, see End DW (2007) *I*: 115–150

Moriarty KJ, Koblish H, Johnson DL, Galemmo Jr RA (2007) Progress in the Development of Agents to Control the Cell Cycle. *I*: 189–271

Paz K, Zhu Z (2007) Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. *I*: 313–362

Sawyer TK (2007) Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy. *I*: 363–385

Sommer A, see Hoffmann J (2007) *I*: 1–64

Wallace EM, Yeh TC, Laird ER, Blake JF, Lyssikatos J (2007) Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. *I*: 65–114

Yeh TC, see Wallace EM (2007) *I*: 65–114

Zhu Z, see Paz K (2007) *I*: 313–362

Subject Index

- Abiraterone 50
Ableson (Abl) kinase 407
Absorption, variable 1, 11
Aclobifene 53
Acute lymphoblastic leukemia (ALL) 3, 408
Acute myeloid leukemia 133
N-Acyl-/aryl-2-aminothiazoles 248
Adaphostin 417
Adrenocorticotrophic hormone (ACTH) 22
AEE788 109, 359
AG1024 418
Aminoglutethimide 35
Aminoimidazo[1,2-*a*]pyridines 240
3-Aminopyrazoles 225
AMN107 411
Anastrozole 5, 35
Androgen receptor 20, 28
Angiogenesis 333
Angiogenesis inhibitor 333
Anti-androgens 64
Anti-apoptotic pathway 171
Anti-estrogens 51
Anti-hormones, targeted drugs 5, 21
Antibodies 333, 339
AP23451 397
AP23464 397, 423
AP23588 397
AP23846 397
AP23848 397, 423
AP23994 397
Arimidex–tamoxifen, alone or in combination 38
Aromatase inhibitor 5, 34
ARRY-142886 (AZD6244) 117
ARRY-334543 106
Asoprisnil 64
Aurora kinases 207, 251
–, inhibitors 256
Aurora-A 252
Aurora-B 255
Axitinib (AG13736) 357
Azasteroides 47
AZD0530 431
BAY57-9352 362
Bazedoxifene 56
Bcr-Abl 407
Bcr-Abl kinase inhibitors 411
Benign prostate hyperplasia 40
2-(Benzimidazol-1-yl)thiazole 277
5-(Benzimidazol-1-yl)thiophene 277
Benzopyranones 182
Benzothiazoles 277
5-Benzoyl-2,4 diaminothiazoles 249
Bevacizumab 9
BIBF1120 360
BIBW 2992 107
Bicalutamide 67
Biochanin A 37
Biomarkers 121, 146
BMS-354825 (Dasatinib) 393, 427
BMS-582664 366
BMS-599626 105
Bortezomib 9
B-Raf 92
CAAX peptide competitive heterocyclic Inhibitors 149
CAAX peptidomimetics 147
cAMP-activating compounds 65
Camptothecin 189
Canertinib 106
Cardiac arrhythmia potential 1, 11
CDKs 209
– inhibitors 212
CDP791 341
Cediranib (AZD2171) 349

- Celecoxib 185
 CEP7055 364
 CGP-76030/CGP-76775 396, 422
 CHIR258 363
 Chronic myelogenous leukemia (CML) 408
 CI-994 (Tacedinaline) 323
 Cisplatin 4
 CML 407
 Co-factors 29
 Complete androgen insensitivity syndrome (CAIS) 29
 COX-2 41, 185
 CP-724714 101
 CPA 68
 CREB-binding protein (CBP) 30
 Cyclic peptides 303
 Cyclin-dependent kinases 207, 209
 Cyclooxygenase 2 41
 – inhibitor 185
 Cyclophosphamide 3
 CYP-17 inhibitors 50
 Cyproterone acetate (CPA) 19, 66
 Cytochrome P450 liability 1, 11
 Cytotoxic drugs 3

 Dasatinib 393
 DC101 339
 Dehydro-epiandrosterone sulfate (DHEAS) 43
 Depsipeptide (FR901228/FK-228) 322
 DHT 46, 50
 Diaminotriazoles 247
 Diaryl ureas 231
 Diethylstilbestrol (DES) 69
 Doxorubicin 5, 189
 Dual aromatase-sulfatase inhibitor (DASI) 37
 Dual inhibitors, Bcr-Abl/Src kinases 418
 Dutasteride 47-49

 Effectors, downstream 138
 EGF signalling pathway, inhibitor 9
 EGFR 89
 –/ErbB2 dual inhibitors 102
 – inhibitor 83
 EMATE 44
 Endocrine feedback cycle 22
 Endocrine therapy 34
 Epidermal growth factor (EGF) 65
 Epidermal growth factor receptor (EGFR) 173, 387
 ErbB family 95
 –, selective inhibitors 83, 96
 ERK 83
 Erlotinib 9, 96
 Estrogen biosynthesis, inhibitor 5
 Estrogen receptors, ER α /ER β 20, 24
 Estrogens 69
 Estrone-3-O-sulfamate (EMATE) 44
 Estrone sulfate (E1S) 43
 Estrone-sulfatase (STS) 43
 Ethinyl estradiol 69
 3-Ethylthiazolidinone 280

 Fadrozole 35
 Farnesyl protein transferase 136
 Farnesyl transferase inhibitors 133, 147
 Finasteride 47
 Flavonoids 37, 271
 5-Fluorouracil 3
 Flutamide 6, 68
 fMEK, inhibitors 117
 Focal adhesion kinase (FAK) 388
 Follicle stimulating hormone (FSH) 22, 70
 FPP competitive compounds 148
 FTase knockout mice 146
 Fulvestrant 55, 58
 Fuopyrazoles 260

 G-protein-coupled receptors (GPCRs) 182
 G2/M growth delay, nuclear proteins 142
 Gefitinib 9, 99
 Glucocorticoid receptor (GR) 51
 Gonadotropin-releasing hormone (GnRH) 22, 70
 Goserelin 6

 HDACs 296
 –, inhibitors 293, 300, 314
 Heat-shock protein inhibitors 195
 Histone acetyltransferases (HATs) 26, 30, 296
 Histone deacetylases (HDACs) 26, 30, 293, 296
 HKI-272 107
 Hormone antagonists 21, 51
 Hormone deprivation 21, 34
 Hormone interference 21, 69
 Hormone release, inhibitors 70

- Hormone response elements (HREs) 28
Hsp90 169
Human placenta estradiol dehydrogenase 41
Hydroxamates 318
Hydroxamic acid 293
– replacements 305
17 β -Hydroxysteroid dehydrogenases 41
– inhibitors 41
- IGF-IR 169, 172
–, kinase inhibitors 174
Imatinib, Bcr-Abl kinase inhibitor, CML 9, 390, 407, 409
IMC-1121B 341
IMC-1C11 340
Imidazopyrazines 262
Imidazopyridines 262
Imidazopyrimidines 181
Imidazolopyrimidines 262
Imidazotriazines 279
Indazoles 260
Indazoles, 3,5-substituted 222
Indeno[1,2-*c*]pyrazol-4-ones 222
Indolinone template-based inhibitor, SU-6656 396
Indolopyrimidines 267
Inositol polyphosphates 169, 194
Insulin-like growth factor (IGF-1) 65
Insulin-like growth factor I receptor 172
Interleukin-6 receptor (IL6-R) 387
Isoform selective 293
- KDR 333, 337, 342
–, target for antiangiogenesis therapy 338
Keratinocyte growth factor (KGF) 65
Kinase inhibitor 83
Kinase insert domain receptor (KDR) 333, 337, 342
Kinase selectivity 383
Kinases 207
–, dual specificity 385
- L21649 366
Lapatinib 102
Lasofoxifene 53
Letrozole 35
Luteinising hormone (LH) 22, 70
Luteinising hormone-releasing hormone (LHRH) 71
- Mechanism-based design 383
MEK1/MEK2 93
MEK inhibitor 83
Metformin 181
Methotrexate 3
N-Methyl piperazine 11
Mifepristone 61
Mineralocorticoid receptor (MR) 23, 51
MS-275 322
mTor 169
Multi-kinase inhibitors 109
- Neovastat (Ae941) 354
Neuropilin (NRP) 336
Nilutamide 68
Nitrogen mustard 3
NR boxes, leucine-rich motifs (LXXLL) 29
NS-187 415
Nuclear proteins, G2/M growth delay 142
- ofmTOR, inhibitors 190
ON012380 416
Onapristone 62
Ospemifene 56
Ovarian estrogen, inhibitor 6
Oxindoles 244, 267
- Paclitaxel 5
Paullones 219
Pazopanib (GW786034) 355
PD0325901 120
PD166326 419
PDK1 169
–, kinase inhibitors 184
Peptides, cyclic 303
2-Phenylaminopyrimidines 409, 411
Phenylureas 279
Phosphatidylinositol 169
Phosphatidylinositol analogues 192
Phosphatidylinositol-3-kinases 169, 178
3-Phosphoinositide-dependent protein kinase-1 183
Phospholipids 169, 194
PI3K 169
–, kinase inhibitors 179
PKB 169
–, kinase inhibitors 187
Placenta growth factor (PlGF) 336
Platinum 4

- Picropodophyllin 176
Polo-like kinases 207, 269
-, inhibitors 271
PP1/PP2 395
Pregnenolone 50
Progesterone receptor 26
Progesterone receptor antagonists (PRAs) 60
Progesterin megestrol acetate (MGA) 70
Progestins 69
Proliferating cell nuclear antigen (PCNA) 57
Prostate Cancer Prevention Trial (PCPT) 49
Protein kinases 8, 169, 186
Protein prenylation 133
Protein tyrosine kinases 385
Purine template-based inhibitors 397
Purvalanol 271, 390
Pyrazoles 256
Pyrazolo[1,5-*a*]pyridines and
Pyrazolo[1,5-*a*]pyrimidines 242
1*H*-Pyrazolo[3,4-*b*]pyridine 220
Pyrazolones 256
Pyrazolopyrimidine template-based
inhibitors 395
Pyridofuopyrimidines 181
Pyrido[2,3-*d*]pyrimidin-7-one 227
Pyridopyrimidinone template-based
inhibitors 395
3-(Pyrimidin-4-yl)imidazo[1,2-*a*]pyridine
237
3-(Pyrimidin-4-yl)imidazo[1,2-*b*]
pyridazines 237
Pyrimidines 233, 274
5*H*-Pyrimidino[5,4-*d*]benzazepines 268
Pyrimidinopyrazines 274
Pyrimidinylaminothiazole template-based
inhibitor 393
Pyrrolocarbazoles 216
Pyrrolopyrazoles 259
Pyrrolopyrimidine template-based
inhibitors CGP-76030/CGP-76775 396
Pyrrolopyrimidines 174, 262

Quinazoline template-based inhibitors
394
Quinazolines 182, 229, 263
Quinoline 266

Quinoline template-based inhibitor
SKI-606 (Bosutinib) 394
Quinox-2(1*H*)-ones 232

Raf, inhibitors 83, 113
Raloxifene 56
Rapamycin 190
Ras proteins 133, 138
Receptor tyrosine kinases 8
5 α -Reductase inhibitors 46
Rheb 144
Rho proteins 141
Rituximab 8
RNA interference (RNAi) therapies 65
RU38486 61

Scytonemin 271
Selective androgen receptor modulators
(SARMs) 67
Selective estrogen receptor modulators
(SERMs) 66
Selective progesterone receptor modulators
(SPRMs) 61
Semaxanib (SU5416) 342
Serine/threonine kinases 11, 385
Sex hormone binding globulin (SHBG) 57
Signal transducer and activator of
transcription-3 (STAT-3) 387
SKI-606 (Bosutinib) 394, 425
Src 383
Src kinases 383, 386
-, inhibitor 399, 409
Staurosporine 187, 271
Steroid hormone biosynthesis, inhibition
34
Steroid hormone receptors 23
-, blockade 51
-, ligand-independent activation 31
Steroid sulfatase inhibitors 43
Steroids, genomic effect 31
Structure-based design 383
SU-6656 342, 396
Sulphur mustard gas 2
Sunitinib (SU11248) 342

T315I 407
Tamoxifen 5, 19, 26, 53, 55
Targeted drugs 6
Template-based inhibitors 388
Testicular androgen, inhibitor 6

- Testosterone 47, 50
Thiazolopyrimidines 262
Thienopyrazoles 260
Toluidides 66
Toremifene 55
Transactivation function, nuclear hormone receptors 29
Transcription factors 23
Transforming growth factor β (TGF- β) receptor 144
Trastuzumab 8
Triazoles 35
Trichostatin A (TSA) 297, 300
Tyrosine kinase 10
Tyrosine kinase inhibitors 333, 342

Vandetanib (ZD6474) 349
Vascular endothelial growth factor (VEGF) 9, 333
Vascular endothelial growth factor receptor (VEGFR) 333, 388
Vascular permeability factor (VPF) 335
Vatalanib (PTK787) 347
VEGF 9, 333
VEGFR 333, 388
VEGFR2 334
-, neutralizing antibodies 339
Vorinostat (SAHA) 319
Vorzole 35
VPF 335

Wortmannin 179

XL647 111, 356
XL999 356

ZD4190 349
ZK304709 365